Slow Bull
The market, slowly. SATURDAY, 26 SEPTEMBER 2026

Spruce Biosciences, Inc.

SPRB Nasdaq SEC CIK 1683553
Follow Spruce Biosciences Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Net income −$16.2M −685.1% vs same quarter last year
EPS, diluted −$6.68 −90.9% vs same quarter last year
Operating cash flow −$22.1M −150.6% vs same quarter last year
Operating income −$16.5M −513.4% vs same quarter last year
Revenue by quarter
$602K
$697K
$0
$0
$0
$0
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$60M−$40M−$20M$0$20MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$0−$39M
FY24$4.9M−$53M
FY23$10.1M−$47.9M
FY22$0−$46.2M
FY21-−$42.3M
FY20-−$29.5M
FY19-−$13.1M
FY18--
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25-
FY24−$56M
FY23−$33.3M
FY22−$41.7M
FY21−$36M
FY20−$27.6M
FY19−$12.6M
FY18-

News

No stories filed under Spruce Biosciences yet - coverage appears here as the news feed clusters it.